Table 5 Odds ratios (95% confidence intervals (CI)) for hormone therapy treatment assignment, and for a doubling of baseline sex hormone and for a doubling from baseline to year 1 of sex hormone values in the Women’s Health Initiative postmenopausal hormone therapy trials
Odds ratio (95% confidence interval) | ||||
|---|---|---|---|---|
CEE + MPA trial* | CEE trial* | |||
Baseline only† | Baseline + year 1† | Baseline only | Baseline + year 1 | |
Treatment | 1.58 (1.13, 2.22) | 1.46 (0.86, 2.47) | 0.62 (0.40, 0.96) | 0.84 (0.43, 1.65) |
Baseline: | ||||
Bioavailable estradiol | 1.41 (1.03, 1.93) | 1.44 (1.03, 2.01) | 1.31 (0.93, 1.84) | 1.24 (0.86, 1.79 |
SHBG* | 1.11 (0.83, 1.50) | 1.13 (0.83, 1.53) | 0.67 (0.47, 0.97) | 0.64 (0.44, 0.83) |
Baseline to year 1 change: | ||||
Bioavailable estradiol | 1.05 (0.81, 1.36) | 0.87 (0.62, 1.23) | ||
SHBG | 1.04 (0.76, 1.43) | 0.85 (0.57, 1.26) | ||
Cases/controls | 254/291 | 254/291 | 161/191 | 161/191 |
CEE + MPA trial | CEE trial | |||
Baseline only | Baseline + year 1 | Baseline only | Baseline + year 1 | |
Treatment | 1.59 (1.10, 2.30) | 1.65 (0.92, 2.97) | 0.71 (0.43, 1.15) | 0.92 (0.41, 2.09) |
Baseline: | ||||
Estradiol | 1.22 (0.71, 1.76) | 1.22 (0.71, 2.08) | 1.56 (0.90, 2.71) | 1.87 (0.97, 3.62) |
Estrone | 1.28 (0.82, 2.01) | 1.20 (0.72, 2.02) | 0.78 (0.43, 1.40) | 0.57 (0.29, 1.12) |
Estrone sulfate | 0.95 (0.69, 1.30) | 0.93 (0.66, 1.31) | 1.09 (0.69, 1.73) | 1.25 (0.76, 2.05) |
SHBG | 0.92 (0.69, 1.23) | 0.92 (0.67, 1.25) | 0.56 (0.38, 0.83) | 0.60 (0.39, 0.90) |
Baseline to year 1 change: | ||||
Estradiol | 1.11 (0.79, 1.56) | 1.18 (0.71, 1.96) | ||
Estrone | 0.95 (0.65, 1.39) | 0.57 (0.35, 0.95) | ||
Estrone sulfate | 0.94 (0.65, 1.37) | 1.50 (0.91, 2.48) | ||
SHBG | 1.00 (0.66, 1.50) | 1.00 (0.56, 1.79) | ||
Cases/controls | 230/248 | 230/248 | 147/151 | 147/151 |